This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.


New contact form

Please complete the form below if you would like more information about ELIQUIS® (apixaban) and one of our sales representatives will contact you in due course. Your contact details will only be used to help your local BMS / Pfizer representative respond to your request.

Please provide the following details

*Required

First name*

Surname*

Professional email address*

Confirmation of email address*

Work postcode*

Which indication are you inquiring about?*
(Select both if applicable)

What topic are you inquiring about?* (Select multiple if applicable)

The information you supply BMS through this form will be held and used by us solely for the purpose of responding to your request and will not be retained for any other purpose. Please read our Privacy Notice here for more information.